Perifosine (KRX-0401)
| Brand Name: | |
| Generic Name: | perifosine |
| Code Name: | KRX-0401 |
| Company: | Keryx Biopharmaceuticals |
| FDA Clinical Phase: | 1, 2, & 3 |
Description:
Perifosine is a novel anti-cancer agent that is being studied for its ability to inhibit Akt, a key signal transduction pathway. Akt is particularly important in the development of cancers, impacting programmed cell death, cell growth, cell differentiation, and cell survival. High levels of activated Akt are frequently observed in many types of cancer, and it is often activated in tumors that are resistant to other anti-cancer therapy. Perifosine does not appear to cause flu-like symptoms, decreases in platelets, or hair loss, which distinguishes it from other novel agents that inhibit the Akt pathway. The most common side effects include nausea, vomiting, diarrhea, and fatigue.
Clinical Trials:
Currently, there are no clinical trials studying perifosine that are recruiting multiple myeloma patients.
Web site for Perifosine: http://www.keryx.com/page.cfm?hmid=20&smid=30&pg=19
Related Articles:
- Perifosine Advances To Phase 3 Multiple Myeloma Clinical Trial
- ASH 2008 – Perifosine Effective Against Multiple Myeloma In Combination With Dexamethasone-Revlimid And Dexamethasone-Velcade
- Perifosine Combination Therapy Is Promising For Relapsed And Refractory Multiple Myeloma (ASH 2009)
- Antibody Treatment In Mice Shows Antitumor Activity
- New Myeloma Drugs Target Different Mechanisms: Signaling Pathways
Leave a comment